Daniel Hochhauser

Professor Daniel Hochhauser is a Professor of Medical Oncology at the Research Department of Oncology, University College London. His work focuses on advancing cancer treatment through clinical trials and translational research across various malignancies.

His educational background includes:

• Doctor of Philosophy from University of Oxford (1993)
• Member of the Royal College of Physicians from Royal College of Physicians (1986)
• Bachelor of Medicine/Bachelor of Surgery from Royal Free University College Medical School (1983)
• Bachelor of Arts from University of Cambridge (1979)

Professor Hochhauser's research spans multiple areas of oncology with particular emphasis on gastrointestinal cancers, targeted therapies, and novel treatment approaches. His work bridges clinical practice with laboratory research to develop more effective cancer treatments. He has made significant contributions to understanding drug resistance mechanisms, developing novel therapeutic strategies, and implementing precision medicine approaches in oncology. His research often involves collaborative efforts across multiple institutions to conduct large-scale clinical trials and translational studies, with notable work on stromal regulation of drug responses using organoid models and molecular profiling for personalized cancer treatment.

Analysis of his recent publications reveals a strong focus on gastrointestinal cancers, particularly pancreatic, colorectal, and gastric cancers, as well as prostate cancer. There's a clear trend toward personalized medicine approaches, with studies examining biomarkers, molecular profiling, and targeted therapies. Many of his publications involve large clinical trials evaluating novel treatment combinations and maintenance therapies across multiple cancer types.

Professor Hochhauser has been instrumental in significant clinical trials including the POLO trial for pancreatic cancer and studies on novel agents like NX-1607, a CBL-B inhibitor. His work often addresses critical questions in cancer treatment sequencing, combination therapies, and overcoming treatment resistance, with numerous publications in high-impact journals such as the New England Journal of Medicine, Cell, and Nature Genetics.